169 related articles for article (PubMed ID: 37702900)
21. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Brose MS; Nutting CM; Jarzab B; Elisei R; Siena S; Bastholt L; de la Fouchardiere C; Pacini F; Paschke R; Shong YK; Sherman SI; Smit JW; Chung J; Kappeler C; Peña C; Molnár I; Schlumberger MJ;
Lancet; 2014 Jul; 384(9940):319-28. PubMed ID: 24768112
[TBL] [Abstract][Full Text] [Related]
22. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
23. Meta-analyses on progression-free survival as a surrogate endpoint for overall survival in triple-negative breast cancer.
Hirai T; Nemoto A; Ito Y; Matsuura M
Breast Cancer Res Treat; 2020 May; 181(1):189-198. PubMed ID: 32246379
[TBL] [Abstract][Full Text] [Related]
24. Surrogate End Points for Overall Survival in Metastatic, Locally Advanced, or Unresectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of 24 Randomized Controlled Trials.
Makris EA; MacBarb R; Harvey DJ; Poultsides GA
Ann Surg Oncol; 2017 Aug; 24(8):2371-2378. PubMed ID: 28397190
[TBL] [Abstract][Full Text] [Related]
25. Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer.
Lux MP; Böhme S; Hücherig S; Jeratsch U; Kürschner N; Lüftner D
Breast Cancer Res Treat; 2019 Aug; 176(3):495-506. PubMed ID: 31065873
[TBL] [Abstract][Full Text] [Related]
26. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
[TBL] [Abstract][Full Text] [Related]
27. Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Yang Y; Wang J; Wang W; Zhang T; Zhao J; Wang Y; Li Y; Wang L; Bi N
Front Oncol; 2022; 12():810580. PubMed ID: 35155246
[TBL] [Abstract][Full Text] [Related]
28. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
[TBL] [Abstract][Full Text] [Related]
29. Surrogacy of progression-free survival (PFS) for overall survival (OS) in esophageal cancer trials with preoperative therapy: Literature-based meta-analysis.
Kataoka K; Nakamura K; Mizusawa J; Kato K; Eba J; Katayama H; Shibata T; Fukuda H
Eur J Surg Oncol; 2017 Oct; 43(10):1956-1961. PubMed ID: 28747249
[TBL] [Abstract][Full Text] [Related]
30. Surrogate Endpoints as Predictors of Overall Survival in Metastatic Urothelial Cancer: A Trial-level Analysis.
Ghali F; Zhao Y; Patel D; Jewell T; Yu EY; Grivas P; Montgomery RB; Gore JL; Etzioni RB; Wright JL
Eur Urol Open Sci; 2023 Jan; 47():58-64. PubMed ID: 36601043
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of progression-free survival as a surrogate end point in primary CNS lymphoma: a systematic review and meta-analysis.
Zhan J; Yang S; Zhang W; Zhou D; Zhao D; Zhang Y; Wang W; Wei C
Future Oncol; 2023 Oct; 19(31):2123-2133. PubMed ID: 37882339
[No Abstract] [Full Text] [Related]
32. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
33. Surufatinib in Chinese Patients with Locally Advanced or Metastatic Differentiated Thyroid Cancer and Medullary Thyroid Cancer: A Multicenter, Open-Label, Phase II Trial.
Chen J; Ji Q; Bai C; Zheng X; Zhang Y; Shi F; Li X; Tang P; Xu Z; Huang R; Huang T; Pan Y; Fan S; Zhou J; Su W
Thyroid; 2020 Sep; 30(9):1245-1253. PubMed ID: 32075524
[No Abstract] [Full Text] [Related]
34. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer.
Michiels S; Pugliano L; Marguet S; Grun D; Barinoff J; Cameron D; Cobleigh M; Di Leo A; Johnston S; Gasparini G; Kaufman B; Marty M; Nekljudova V; Paluch-Shimon S; Penault-Llorca F; Slamon D; Vogel C; von Minckwitz G; Buyse M; Piccart M
Ann Oncol; 2016 Jun; 27(6):1029-1034. PubMed ID: 26961151
[TBL] [Abstract][Full Text] [Related]
35. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
36. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Pilz LR; Manegold C; Schmid-Bindert G
Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
Mushti SL; Mulkey F; Sridhara R
Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
[No Abstract] [Full Text] [Related]
38. Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ; Kim KW
Korean J Radiol; 2020 Apr; 21(4):471-482. PubMed ID: 32193895
[TBL] [Abstract][Full Text] [Related]
39. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
40. Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer.
Kim MJ; Kim SM; Lee EK; Hwangbo Y; Lee YJ; Cho SW; Park DJ; Lee Y; Park YJ
Endocr J; 2019 Jul; 66(7):597-604. PubMed ID: 31006722
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]